Dapagliflozin works through inhibiting sodium-glucose transporter 2 (SGLT2), a protein in the kidney that reabsorbs glucose into the bloodstream. This allows extra glucose to be excreted through the urine, improving glycemic control without increasing insulin secretion.
*The following content is generated by AI and is for reference only.
Overview
Dapagliflozin is a potent SGLT2 inhibitor used in pharmaceutical synthesis. Its molecular formula is C21H25NO8 and CAS number is 872304-90-0.
Application
- Diabetes Management: Adjunct therapy for Type 2 diabetes to control blood glucose.
- Cardiovascular Care: Treatment of chronic heart failure to reduce hospitalization risks.
- Nephrology: Slowing progression of diabetic kidney disease.
Precautions
Contraindicated in severe renal impairment or end-stage renal disease. Store in a cool, dry place below 25°C away from moisture. Handle with appropriate PPE due to potential reproductive toxicity.